SFI
KURA icon

Susquehanna Fundamental Investments’s Kura Oncology KURA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,754
Closed -$507K – 971
2024
Q1 		$507K Buy
+23,754
New +$462K 0.02% 465

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Susquehanna Fundamental Investments's KURA Position: Q2 2024 in Review

Susquehanna Fundamental Investments sold out of Kura Oncology (KURA) in Q2 2024, closing a stake of 23,754 shares — an estimated $507K sold.

Susquehanna Fundamental Investments first reported a position in KURA in Q1 2024 and held it in 1 quarter. The position peaked at $507K in Q1 2024. 174 funds tracked by Wall St. Rank hold KURA as of Q2 2024.

  • Susquehanna Fundamental Investments reported no remaining Kura Oncology position as of Q2 2024 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 23,754 Kura Oncology shares in Q2 2024, an estimated $507K.
  • Susquehanna Fundamental Investments first reported a position in Kura Oncology in Q1 2024 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Kura Oncology position peaked at $507K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.